DSOL (Drug Free Solution) YoY EBITDA Growth: 25.00% (As of Feb. 2014)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Drug Free Solution YoY EBITDA Growth?

Drug Free Solution DSOL +100.00% YoY EBITDA Growth is 25.00% as of Feb. 2014.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Drug Free Solution's YoY EBITDA Growth for the quarter that ended in Feb. 2014 was 25.00%.

Drug Free Solution's EBITDA per Share for the three months ended in Feb. 2014 was $-0.00.

Drug Free Solution YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Drug Free Solution's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Drug Free Solution YoY EBITDA Growth Chart

Drug Free Solution Annual Data
Trend May12 May13
YoY EBITDA Growth
0.00 -10.00

Drug Free Solution Quarterly Data
Aug11 Nov11 Feb12 May12 Aug12 Nov12 Feb13 May13 Aug13 Nov13 Feb14
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 50.00 -600.00 80.00 0.00 25.00

Drug Free Solution YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Drug Free Solution's YoY EBITDA Growth for the fiscal year that ended in May. 2013 is calculated as:

YoY EBITDA Growth (A: May. 2013 )
=(EBITDA per Share (A: May. 2013 )-EBITDA per Share (A: May. 2012 ))/ | EBITDA per Share (A: May. 2012 ) |
=(-0.011--0.01)/ | -0.01 |
=-10.00 %

Drug Free Solution's YoY EBITDA Growth for the quarter that ended in Feb. 2014 is calculated as:

YoY EBITDA Growth (Q: Feb. 2014 )
=(EBITDA per Share (Q: Feb. 2014 )-EBITDA per Share (Q: Feb. 2013 )) / | EBITDA per Share (Q: Feb. 2013 )) |
=(-0.003--0.004)/ | -0.004 |
=25.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 25.00% mean?
Drug Free Solution (DSOL) has a YoY EBITDA Growth of 25.00% as of Feb. 2014. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Drug Free Solution and its competitors.
Is Drug Free Solution's YoY EBITDA Growth too high?
Drug Free Solution's current YoY EBITDA Growth is 25.00%.
How does Drug Free Solution's YoY EBITDA Growth compare to USEL and ZZLL?
Drug Free Solution's YoY EBITDA Growth of 25.00% can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Healthcare Providers & Services company?
A good YoY EBITDA Growth depends on the Healthcare Providers & Services industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Drug Free Solution and its competitors. Drug Free Solution's current YoY EBITDA Growth is 25.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Drug Free Solution stock overvalued right now?
Drug Free Solution (DSOL) has a current YoY EBITDA Growth of 25.00%. The current YoY EBITDA Growth is 25.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Drug Free Solution (DSOL), the current YoY EBITDA Growth is 25.00% as of Feb. 2014. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Drug Free Solution Business Description

Address 2211 Michelson Drive, Irvine, CA, USA, 92612
Drug Free Solution Inc is a United States based holding company that owns and operates various subsidiaries in the healthcare industry. It is focused on acquiring healthcare operations that focus on Home Healthcare, Developmental Disabilities, Hospice Care, Skilled Nursing, Residential Rehabilitation, Home & Community Based Services.